SEC Form 4 · accession 0001144204-15-051625
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicole Williams
Director
Period of report
Aug 20, 2015
Accepted (ET)
Aug 24, 2015 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 20, 2015 | M | 109 | $9.8223 | A | 1,071 | D | |
| Common Stock | Aug 20, 2015 | M | 865 | $9.8223 | A | 1,936 | D | |
| Common Stock | Aug 20, 2015 | S | 974 | $206.85 | D | 962 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF2 | $9.8223 | Aug 20, 2015 | M | 109 | D | — | Sep 18, 2018 | Common Stock | 109 | 0 | D |
| Options to Purchase Common StockF2 | $9.8223 | Aug 20, 2015 | M | 865 | D | — | Sep 16, 2019 | Common Stock | 865 | 3,894 | D |
Explanation of responses
- F1The reported transaction was made pursuant to a 10(b)5-1 plan adopted by the reporting person on November 21, 2014.
- F2All shares underlying this option have vested.